

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.	Client Ref.
		056291-5038	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>MAR 11 2004 JC34</i>		Applicant: CAMERON et al.	
		Appln. No.: 09/889,409	
		Filing Date: February 22, 2002	
		Date: March 11, 2004	Page 1 of 1

U.S. PATENT DOCUMENTS							
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)	
AR							
BR							
CR							
DR							

FOREIGN PATENT DOCUMENTS					English Abstract	Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No
ER							
FR							

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)		
(W)	GR	McClellan et al., "Candesartan Cilexetil A Review of its Use in Essential Hypertension", Drugs, 1998, pp. 847-869
(W)	HR	Graham-Smith et al., "Oxford Handbook on Clinical Pharmacology and Pharmacotherapy", Moscow, "Meditsina" 2000, part 10 (Partial Translation)
(W)	IR	Balabolkin, "Endocrinology", Moscow, "Universum Publishing" 1998, pp 427-430 and 420-421 (Partial Translation)
(W)	JR	Small Medical Encyclopedia, Moscow, "Meditsina", 199 pp. 110 (Partial Translation)
	KR	
	LR	
	MR	
	NR	
	OR	
	PR	

Examiner <i>Ko-Weddington</i>	Date Considered: 9-7-04
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	